Long COVID continues to affect a significant number of COVID-19 survivors. Mesenchymal stem cells (MSCs) are being explored as a potential treatment due to their unique anti-inflammatory and regenerative properties.
The article highlights how MSC therapy aims to reduce inflammation and repair tissue damage caused by the virus. Clinical studies on MSCs have shown promising results in improving outcomes for severe COVID-19 cases, particularly by addressing lung inflammation and other systemic effects of the virus. Researchers have investigated MSCs’ potential for managing long COVID symptoms.
Ongoing clinical trials are testing the efficacy and safety of MSC therapy for long COVID. While preliminary results are encouraging, the article emphasizes that stem cell therapy remains experimental. Experts caution that more rigorous research is needed before MSC treatments can be widely adopted.
For now, patients interested in this approach should consult medical professionals and consider the current evidence carefully. As research progresses, MSC therapy may become a viable option for alleviating the long-term effects of COVID
